NervGen Pharma (NGEN) Competitors

$3.77 +0.11 (+3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$3.78 +0.00 (+0.13%)

As of 07:38 PM Eastern

NGEN vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

Should you be buying NervGen Pharma stock or one of its competitors? The main competitors of NervGen Pharma include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Avidity Biosciences (RNA). These companies are all part of the "pharmaceutical products" industry.

How does NervGen Pharma compare to Ainos?

Ainos (NASDAQ:AIMDW) and NervGen Pharma (NASDAQ:NGEN) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

: Company Net Margins Return on Equity Return on Assets
Ainos N/A N/A N/A
NervGen Pharma N/A N/A N/A
: NervGen Pharma has a consensus target price of $18.00, indicating a potential upside of 377.45%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NervGen Pharma is more favorable than Ainos.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ainos
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
NervGen Pharma
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

2 Strong Buy rating(s)
2.75
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Ainos $124.16K N/A N/A N/A N/A
NervGen Pharma N/A N/A N/A N/A N/A
: In the previous week, NervGen Pharma had 14 more articles in the media than Ainos. MarketBeat recorded 14 mentions for NervGen Pharma and 0 mentions for Ainos. NervGen Pharma's average media sentiment score of 1.03 beat Ainos' score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the news media.
Company Overall Sentiment
Ainos Neutral
NervGen Pharma Positive

Company	Net Margins	Return on Equity	Return on Assets
Ainos	N/A	N/A	N/A
NervGen Pharma	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$124.16K	N/A	N/A	N/A	N/A
NervGen Pharma	N/A	N/A	N/A	N/A	N/A

Company	Overall Sentiment
Ainos	Neutral
NervGen Pharma	Positive

Summary

NervGen Pharma beats Ainos on 5 of the 6 factors compared between the two stocks.

How does NervGen Pharma compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and NervGen Pharma (NASDAQ:NGEN) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

: Company Net Margins Return on Equity Return on Assets
Alvotech N/A N/A N/A
NervGen Pharma N/A N/A N/A
: NervGen Pharma has a consensus target price of $18.00, indicating a potential upside of 377.45%. Given NervGen Pharma's stronger consensus rating and higher probable upside, analysts plainly believe NervGen Pharma is more favorable than Alvotech.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alvotech
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
NervGen Pharma
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

2 Strong Buy rating(s)
2.75
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alvotech $586.32M N/A N/A N/A N/A
NervGen Pharma N/A N/A N/A N/A N/A
: In the previous week, NervGen Pharma had 14 more articles in the media than Alvotech. MarketBeat recorded 14 mentions for NervGen Pharma and 0 mentions for Alvotech. NervGen Pharma's average media sentiment score of 1.03 beat Alvotech's score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the news media.
Company Overall Sentiment
Alvotech Neutral
NervGen Pharma Positive

Company	Net Margins	Return on Equity	Return on Assets
Alvotech	N/A	N/A	N/A
NervGen Pharma	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alvotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alvotech	$586.32M	N/A	N/A	N/A	N/A
NervGen Pharma	N/A	N/A	N/A	N/A	N/A

Company	Overall Sentiment
Alvotech	Neutral
NervGen Pharma	Positive

Summary

NervGen Pharma beats Alvotech on 5 of the 6 factors compared between the two stocks.

How does NervGen Pharma compare to Aravive?

Aravive (NASDAQ:ARAV) and NervGen Pharma (NASDAQ:NGEN) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

: In the previous week, NervGen Pharma had 14 more articles in the media than Aravive. MarketBeat recorded 14 mentions for NervGen Pharma and 0 mentions for Aravive. NervGen Pharma's average media sentiment score of 1.03 beat Aravive's score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the news media.
Company Overall Sentiment
Aravive Neutral
NervGen Pharma Positive
: Company Net Margins Return on Equity Return on Assets
Aravive N/A N/A N/A
NervGen Pharma N/A N/A N/A
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aravive N/A N/A N/A -$0.90 N/A
NervGen Pharma N/A N/A N/A N/A N/A
: NervGen Pharma has a consensus target price of $18.00, indicating a potential upside of 377.45%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NervGen Pharma is more favorable than Aravive.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aravive
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
NervGen Pharma
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

2 Strong Buy rating(s)
2.75
: 35.8% of Aravive shares are held by institutional investors. 60.4% of Aravive shares are held by insiders. Comparatively, 5.8% of NervGen Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Overall Sentiment
Aravive	Neutral
NervGen Pharma	Positive

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
NervGen Pharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
NervGen Pharma	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

Summary

NervGen Pharma beats Aravive on 5 of the 7 factors compared between the two stocks.

How does NervGen Pharma compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and NervGen Pharma (NASDAQ:NGEN) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

: Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. II N/A N/A N/A
NervGen Pharma N/A N/A N/A
: Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Atlantic Coastal Acquisition Corp. II N/A N/A N/A N/A N/A
NervGen Pharma N/A N/A N/A N/A N/A
: NervGen Pharma has a consensus target price of $18.00, indicating a potential upside of 377.45%. Given NervGen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NervGen Pharma is more favorable than Atlantic Coastal Acquisition Corp. II.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atlantic Coastal Acquisition Corp. II
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
NervGen Pharma
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

2 Strong Buy rating(s)
2.75
: In the previous week, NervGen Pharma had 14 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 14 mentions for NervGen Pharma and 0 mentions for Atlantic Coastal Acquisition Corp. II. NervGen Pharma's average media sentiment score of 1.03 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the news media.
Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
NervGen Pharma Positive

Company	Net Margins	Return on Equity	Return on Assets
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A
NervGen Pharma	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A
NervGen Pharma	N/A	N/A	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atlantic Coastal Acquisition Corp. II	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75

Company	Overall Sentiment
Atlantic Coastal Acquisition Corp. II	Neutral
NervGen Pharma	Positive

Summary

NervGen Pharma beats Atlantic Coastal Acquisition Corp. II on 5 of the 5 factors compared between the two stocks.

How does NervGen Pharma compare to Avidity Biosciences?

NervGen Pharma (NASDAQ:NGEN) and Avidity Biosciences (NASDAQ:RNA) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

: NervGen Pharma has a net margin of 0.00% compared to Avidity Biosciences' net margin of -3,650.39%. NervGen Pharma's return on equity of 0.00% beat Avidity Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
NervGen Pharma N/A N/A N/A
Avidity Biosciences -3,650.39% -44.92% -39.57%
: NervGen Pharma has higher earnings, but lower revenue than Avidity Biosciences.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NervGen Pharma N/A N/A N/A N/A N/A
Avidity Biosciences $18.62M N/A -$322.30M N/A N/A
: NervGen Pharma presently has a consensus target price of $18.00, suggesting a potential upside of 377.45%. Avidity Biosciences has a consensus target price of $69.42, suggesting a potential upside of 437.73%. Given Avidity Biosciences' higher possible upside, analysts plainly believe Avidity Biosciences is more favorable than NervGen Pharma.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NervGen Pharma
1 Sell rating(s)
1 Hold rating(s)

0 Buy rating(s)

2 Strong Buy rating(s)
2.75
Avidity Biosciences
1 Sell rating(s)

12 Hold rating(s)

5 Buy rating(s)

1 Strong Buy rating(s)
2.32
: In the previous week, NervGen Pharma had 13 more articles in the media than Avidity Biosciences. MarketBeat recorded 14 mentions for NervGen Pharma and 1 mentions for Avidity Biosciences. NervGen Pharma's average media sentiment score of 1.03 beat Avidity Biosciences' score of 0.00 indicating that NervGen Pharma is being referred to more favorably in the media.
Company Overall Sentiment
NervGen Pharma Positive
Avidity Biosciences Neutral

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	N/A	N/A
Avidity Biosciences	-3,650.39%	-44.92%	-39.57%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	N/A	N/A	N/A
Avidity Biosciences	$18.62M	N/A	-$322.30M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
Avidity Biosciences	1 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32

Company	Overall Sentiment
NervGen Pharma	Positive
Avidity Biosciences	Neutral

Summary

NervGen Pharma beats Avidity Biosciences on 7 of the 10 factors compared between the two stocks.

Get NervGen Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGEN vs. The Competition

Export

Metric	NervGen Pharma	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	N/A	$886.55M	$4.22B	$11.77B
Dividend Yield	N/A	4.84%	5.87%	5.26%
P/E Ratio	N/A	1.71	23.37	27.07
Price / Sales	N/A	120.63	162.12	75.42
Price / Cash	N/A	20.07	52.08	53.90
Price / Book	N/A	7.60	37.87	6.69
Net Income	N/A	-$4.80M	$114.66M	$332.64M
7 Day Performance	-2.84%	-0.05%	1.21%	2.01%
1 Month Performance	N/A	5.50%	5.50%	9.19%
1 Year Performance	N/A	30.96%	18.68%	39.59%

NervGen Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGEN NervGen Pharma	N/A	$3.77 +3.0%	$18.00 +377.5%	N/A	$0.00	N/A	N/A	N/A	News Coverage Positive News Analyst Upgrade
AIMDW Ainos	N/A	$0.11 flat	N/A	N/A	$0.00	$124.16K	N/A	40	Positive News Gap Down
ALVOW Alvotech	N/A	$0.21 flat	N/A	N/A	$0.00	$586.32M	N/A	4	Upcoming Earnings Gap Up High Trading Volume
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.00 flat	N/A	N/A	$0.00	N/A	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGEN) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NervGen Pharma (NGEN) Competitors

NGEN vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

How does NervGen Pharma compare to Ainos?

Summary

How does NervGen Pharma compare to Alvotech?

Summary

How does NervGen Pharma compare to Aravive?

Summary

How does NervGen Pharma compare to Atlantic Coastal Acquisition Corp. II?

Summary

How does NervGen Pharma compare to Avidity Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NervGen Pharma (NGEN) Competitors

NGEN vs. AIMDW, ALVOW, ARAV, ACABW, and RNA

How does NervGen Pharma compare to Ainos?

Summary

How does NervGen Pharma compare to Alvotech?

Summary

How does NervGen Pharma compare to Aravive?

Summary

How does NervGen Pharma compare to Atlantic Coastal Acquisition Corp. II?

Summary

How does NervGen Pharma compare to Avidity Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGEN vs. The Competition

NervGen Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools